VanEck Video Gaming and eSports ETF vs Exelixis Inc. Common Stock — how do they compare? VanEck Video Gaming and eSports ETF trades at $99.92 (market cap $248.06M), while Exelixis Inc. Common Stock trades at $60.17 (market cap $14.62B). The key difference: Exelixis Inc. Common Stock is far larger — about 58.9× VanEck Video Gaming and eSports ETF's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Video Gaming and eSports ETF for 66 Days and Exelixis Inc. Common Stock for 1 Days on average.
| ESPO | EXEL | |
|---|---|---|
Market Cap | $248.06M | $14.62B |
Volume | 13,622 | 2,684,957 |
Sector | Sector/Thematic | Health |
52-Week High | $118.68 | $59.13 |
52-Week Low | $85.25 | $34.54 |
Typical Hold Time | 66 Days | 1 Days |
Enterprise Value | — | $13.95B |
Signals from Pluang's Aura AI — not financial advice
ESPO trades at $97.32, down 0.33% on the day, with a bullish technical signal from moving averages and neutral oscillators. Key support is at $97 and resistance at $98. Financial ratios are unavailable in the provided data, limiting fundamental insight. No recent news is available to drive sentiment.
The outlook is mixed: technicals suggest upward momentum, but the absence of fundamental data and recent news creates uncertainty. Risks include market volatility and lack of visibility on financial health. Investors need updated earnings and guidance for a clearer investment case.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →